Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMNM, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2027-04-28 | varegacestat | adults with desmoid tumors and assigned a PDUFA target actio | NDA | 63% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Varegacestat (AL102) | Desmoid | Phase 2/3 · NCT04871282 | Active not recruiting |
| Lutetium Lu 177-labeled FAP-targeting Ligand… | Solid Malignancies | Phase 1 · NCT07505771 | Recruiting |
| Anti-ROR1 Antibody-drug Conjugate IM-1021 | Solid Malignancies | Phase 1 · NCT06823167 | Recruiting |
| IM-1340 | Colorectal Cancer | Phase 1 · NCT07890246 | Not yet recruiting |
| IM-1617 | Colorectal Cancer | Phase 1 · NCT07578571 | Recruiting |
| IMM-BCP-01 | SARS-CoV2 Infection | Phase 1 · NCT05429021 | Terminated |
| Moxifloxacin | Healthy Volunteer | Phase 1 · NCT06855264 | Completed |
| Varegacestat Reference Formulation | Healthy | Phase 1 · NCT07610005 | Recruiting |
| Varegacestat Test Formulation A | Healthy | Phase 1 · NCT07610005 | Recruiting |
| Varegacestat Test Formulation B | Healthy | Phase 1 · NCT07610005 | Recruiting |
| Varegacestat Test Formulation C | Healthy | Phase 1 · NCT07610005 | Recruiting |
Also used in these trials (approved or third-party drugs, not IMNM's own candidates): Itraconazole.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMNM holds $461.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $61.2M/quarter from operations, an estimated runway of 22.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMNM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc | Institution (13G, 5%+) | 19,676,883 | 16.67% | 2026-06-30 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 6,041,333 | 5.12% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 5,725,578 | 4.85% | 2026-09-30 |
| Immunome Aggregator, LP | 5%+ holder (13D) | 4,768,583 | 4.04% | 2025-01-31 |
| Clay B Siegall President and CEO, Director · +360,000 options |
Insider | 870,704 | 0.74% | 2026-07-23 |
| Philip Wagenheim Director · +9,897 options |
Insider | 341,147 | 0.29% | 2026-03-20 |
| Max Rosett Chief Financial Officer · +361,500 options |
Insider | 101,287 | 0.09% | 2026-07-23 |
| Isaac Barchas Director · +9,897 options |
Insider | 92,211 | 0.08% | 2026-08-10 |
| Philip Tsai Chief Technical Officer · +266,500 options |
Insider | 81,550 | 0.07% | 2026-07-23 |
| Robert Lechleider Chief Medical Officer · +398,000 options |
Insider | 69,805 | 0.06% | 2026-07-23 |
| Jack Higgins Chief Scientific Officer · +362,180 options |
Insider | 59,250 | 0.05% | 2026-09-11 |
| Sandra G. Stoneman CHIEF LEGAL OFFICER & GC · +76,500 options |
Insider | 43,805 | 0.04% | 2026-07-23 |
Share count 118,072,943 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMNM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →